- Home
- CYCN vs APM Comparison
CYCN vs APM Comparison
Compare CYCN & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- APM
- Stock Information
- Founded
- CYCN 2018
- APM 2010
- Country
- CYCN United States
- APM United Kingdom
- Employees
- CYCN N/A
- APM N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- APM Health Care
- Exchange
- CYCN Nasdaq
- APM Nasdaq
- Market Cap
- CYCN 6.5M
- APM 6.1M
- IPO Year
- CYCN N/A
- APM 2018
- Fundamental
- Price
- CYCN $3.18
- APM $1.07
- Analyst Decision
- CYCN
- APM
- Analyst Count
- CYCN 0
- APM 0
- Target Price
- CYCN N/A
- APM N/A
- AVG Volume (30 Days)
- CYCN 20.7K
- APM 81.2K
- Earning Date
- CYCN 05-06-2025
- APM 06-17-2025
- Dividend Yield
- CYCN N/A
- APM N/A
- EPS Growth
- CYCN N/A
- APM N/A
- EPS
- CYCN N/A
- APM N/A
- Revenue
- CYCN $2,081,000.00
- APM N/A
- Revenue This Year
- CYCN N/A
- APM N/A
- Revenue Next Year
- CYCN N/A
- APM N/A
- P/E Ratio
- CYCN N/A
- APM N/A
- Revenue Growth
- CYCN N/A
- APM N/A
- 52 Week Low
- CYCN $1.27
- APM $0.46
- 52 Week High
- CYCN $9.47
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- CYCN 53.92
- APM 58.89
- Support Level
- CYCN $3.04
- APM $0.83
- Resistance Level
- CYCN $3.26
- APM $1.35
- Average True Range (ATR)
- CYCN 0.25
- APM 0.12
- MACD
- CYCN 0.01
- APM 0.02
- Stochastic Oscillator
- CYCN 80.00
- APM 46.97
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.